TrivarX Ltd
TRI
Company Profile
Business description
TrivarX Ltd is a health technology company developing AI-driven, scientifically-based devices for screening and diagnosis of behavioral health conditions. Trivarx’s clinical research has enabled the development of cutting-edge proprietary algorithms for spectral analyses of sleep architecture and heart rate variability. The Company has one operating segment, being the research, development and commercialisation of its software asaService product, and two geographical locations, being Australia and the United States.
Contact
647 Beaufort Street
Mount LawleyWA6050
AUST: +61 861891155
Sector
Healthcare
Stock type
Defensive
Industry
Health Information Services
Fiscal Year End
Employees
4
Stocks News & Analysis
stocks
Nvidia: Hugging Face acquisition both a wise offensive and defensive move
We think this improves Nvidia’s position within the open-source community.
stocks
Anthropic’s IPO will be huge—and risky. Here are the challenges investors should watch
Part two of a Q&A with PitchBook senior analyst Harrison Rolfes about Anthropic, the AI giant’s challenges, and how much it’s worth.
stocks
Chart of the Week: China demand for copper falls amidst record rally
Elevated copper prices raise valuation questions.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,196.00 | 54.60 | -0.59% |
| CAC 40 | 8,278.77 | 7.63 | -0.09% |
| DAX 40 | 26,046.40 | 43.08 | 0.17% |
| Dow JONES (US) | 53,414.25 | 271.86 | -0.51% |
| FTSE 100 | 10,831.09 | 0.43 | -0.00% |
| HKSE | 25,650.87 | 437.56 | 1.74% |
| NASDAQ | 26,506.99 | 77.07 | -0.29% |
| Nikkei 225 | 65,020.94 | 806.46 | 1.26% |
| NZX 50 Index | 13,974.18 | 128.00 | 0.92% |
| S&P 500 | 7,718.60 | 29.11 | -0.38% |
| S&P/ASX 200 | 9,005.90 | 64.30 | -0.71% |
| SSE Composite Index | 3,930.12 | 11.97 | -0.30% |